Behavioural sensitisation during dopamine replacement therapy in Parkinson's disease is reminiscent of the addicted brain

F. Biagioni, A. Pellegrini, S. Ruggieri, L. Murri, A. Paparelli, F. Fornai

Research output: Contribution to journalArticle

Abstract

The intermittent oral intake of the dopamine (DA) precursor L-3,4-dihydroxyphenylalanine (L-DOPA) is the classic therapy of Parkinson's disease (PD). In this way, the drug precursor can be metabolised into the active neurotransmitter DA. Although this occurs throughout the brain, the therapeutic relief is believed to be due to restoring extracellular DA levels within the dorsal striatum (more in the putamen than the caudate nucleus) which lacks endogenous DA as a consequence of the disease process. However, differing from physiological DA transmission, this therapeutic pattern leads to abnormal peaks of non-synaptic DA, which are supposed to trigger behavioural sensitisation expressed as abnormal involuntary movements. A similar pattern of abnormal DA stimulation occurs during methamphetamine (METH) intake. In the present review we will provide evidence showing the similarities between METH- and L-DOPAinduced DA stimulation with an intact and denervated striatum respectively. This comparison will encompass various features; the timing, the areas and the amount of extracellular DA levels which reveal surprising homologies. Such an overlapping between L-DOPA in PD and METH will be further analysed to critically assess the commonalities concerning the following points: abnormal receptor stimulation, recruitment of altered transduction pathways, abnormal gene expression, alterations in the phenotype of striatal neurons, and the establishment of behavioural sensitisation which appear as distinct phenomena (i.e. abnormal involuntary movements in PD and drug addiction in METH abuse); nonetheless, this may also lead to common behavioural alterations (METH-like addictive behaviours in PD patients during the course of DA replacement therapy in subsets of PD patients).

Original languageEnglish
Pages (from-to)894-902
Number of pages9
JournalCurrent Topics in Medicinal Chemistry
Volume9
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Parkinson Disease
Dopamine
Methamphetamine
Brain
Dyskinesias
Therapeutics
Levodopa
Addictive Behavior
Corpus Striatum
Caudate Nucleus
Putamen
Prodrugs
Substance-Related Disorders
Neurotransmitter Agents
Phenotype
Gene Expression
Neurons

Keywords

  • Addiction
  • Behavioural sensitisation
  • Delta fosB
  • Dopamine
  • Dyskinesia
  • L-DOPA
  • Methamphetamine
  • Parkinson's disease

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Behavioural sensitisation during dopamine replacement therapy in Parkinson's disease is reminiscent of the addicted brain. / Biagioni, F.; Pellegrini, A.; Ruggieri, S.; Murri, L.; Paparelli, A.; Fornai, F.

In: Current Topics in Medicinal Chemistry, Vol. 9, No. 10, 2009, p. 894-902.

Research output: Contribution to journalArticle

@article{1a299637548c4f9686100a7f107f2840,
title = "Behavioural sensitisation during dopamine replacement therapy in Parkinson's disease is reminiscent of the addicted brain",
abstract = "The intermittent oral intake of the dopamine (DA) precursor L-3,4-dihydroxyphenylalanine (L-DOPA) is the classic therapy of Parkinson's disease (PD). In this way, the drug precursor can be metabolised into the active neurotransmitter DA. Although this occurs throughout the brain, the therapeutic relief is believed to be due to restoring extracellular DA levels within the dorsal striatum (more in the putamen than the caudate nucleus) which lacks endogenous DA as a consequence of the disease process. However, differing from physiological DA transmission, this therapeutic pattern leads to abnormal peaks of non-synaptic DA, which are supposed to trigger behavioural sensitisation expressed as abnormal involuntary movements. A similar pattern of abnormal DA stimulation occurs during methamphetamine (METH) intake. In the present review we will provide evidence showing the similarities between METH- and L-DOPAinduced DA stimulation with an intact and denervated striatum respectively. This comparison will encompass various features; the timing, the areas and the amount of extracellular DA levels which reveal surprising homologies. Such an overlapping between L-DOPA in PD and METH will be further analysed to critically assess the commonalities concerning the following points: abnormal receptor stimulation, recruitment of altered transduction pathways, abnormal gene expression, alterations in the phenotype of striatal neurons, and the establishment of behavioural sensitisation which appear as distinct phenomena (i.e. abnormal involuntary movements in PD and drug addiction in METH abuse); nonetheless, this may also lead to common behavioural alterations (METH-like addictive behaviours in PD patients during the course of DA replacement therapy in subsets of PD patients).",
keywords = "Addiction, Behavioural sensitisation, Delta fosB, Dopamine, Dyskinesia, L-DOPA, Methamphetamine, Parkinson's disease",
author = "F. Biagioni and A. Pellegrini and S. Ruggieri and L. Murri and A. Paparelli and F. Fornai",
year = "2009",
doi = "10.2174/156802609789378245",
language = "English",
volume = "9",
pages = "894--902",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Behavioural sensitisation during dopamine replacement therapy in Parkinson's disease is reminiscent of the addicted brain

AU - Biagioni, F.

AU - Pellegrini, A.

AU - Ruggieri, S.

AU - Murri, L.

AU - Paparelli, A.

AU - Fornai, F.

PY - 2009

Y1 - 2009

N2 - The intermittent oral intake of the dopamine (DA) precursor L-3,4-dihydroxyphenylalanine (L-DOPA) is the classic therapy of Parkinson's disease (PD). In this way, the drug precursor can be metabolised into the active neurotransmitter DA. Although this occurs throughout the brain, the therapeutic relief is believed to be due to restoring extracellular DA levels within the dorsal striatum (more in the putamen than the caudate nucleus) which lacks endogenous DA as a consequence of the disease process. However, differing from physiological DA transmission, this therapeutic pattern leads to abnormal peaks of non-synaptic DA, which are supposed to trigger behavioural sensitisation expressed as abnormal involuntary movements. A similar pattern of abnormal DA stimulation occurs during methamphetamine (METH) intake. In the present review we will provide evidence showing the similarities between METH- and L-DOPAinduced DA stimulation with an intact and denervated striatum respectively. This comparison will encompass various features; the timing, the areas and the amount of extracellular DA levels which reveal surprising homologies. Such an overlapping between L-DOPA in PD and METH will be further analysed to critically assess the commonalities concerning the following points: abnormal receptor stimulation, recruitment of altered transduction pathways, abnormal gene expression, alterations in the phenotype of striatal neurons, and the establishment of behavioural sensitisation which appear as distinct phenomena (i.e. abnormal involuntary movements in PD and drug addiction in METH abuse); nonetheless, this may also lead to common behavioural alterations (METH-like addictive behaviours in PD patients during the course of DA replacement therapy in subsets of PD patients).

AB - The intermittent oral intake of the dopamine (DA) precursor L-3,4-dihydroxyphenylalanine (L-DOPA) is the classic therapy of Parkinson's disease (PD). In this way, the drug precursor can be metabolised into the active neurotransmitter DA. Although this occurs throughout the brain, the therapeutic relief is believed to be due to restoring extracellular DA levels within the dorsal striatum (more in the putamen than the caudate nucleus) which lacks endogenous DA as a consequence of the disease process. However, differing from physiological DA transmission, this therapeutic pattern leads to abnormal peaks of non-synaptic DA, which are supposed to trigger behavioural sensitisation expressed as abnormal involuntary movements. A similar pattern of abnormal DA stimulation occurs during methamphetamine (METH) intake. In the present review we will provide evidence showing the similarities between METH- and L-DOPAinduced DA stimulation with an intact and denervated striatum respectively. This comparison will encompass various features; the timing, the areas and the amount of extracellular DA levels which reveal surprising homologies. Such an overlapping between L-DOPA in PD and METH will be further analysed to critically assess the commonalities concerning the following points: abnormal receptor stimulation, recruitment of altered transduction pathways, abnormal gene expression, alterations in the phenotype of striatal neurons, and the establishment of behavioural sensitisation which appear as distinct phenomena (i.e. abnormal involuntary movements in PD and drug addiction in METH abuse); nonetheless, this may also lead to common behavioural alterations (METH-like addictive behaviours in PD patients during the course of DA replacement therapy in subsets of PD patients).

KW - Addiction

KW - Behavioural sensitisation

KW - Delta fosB

KW - Dopamine

KW - Dyskinesia

KW - L-DOPA

KW - Methamphetamine

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=74249089693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249089693&partnerID=8YFLogxK

U2 - 10.2174/156802609789378245

DO - 10.2174/156802609789378245

M3 - Article

C2 - 19754404

AN - SCOPUS:74249089693

VL - 9

SP - 894

EP - 902

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 10

ER -